Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MLYCD | O95822 | 8/20 | 0.57 |
| ▸ | RORC | P51449 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RORA | P35398 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843322 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2MLYCDRORCTP53 | |
| SCHEMBL3302544 | 0.82 | POLB (0.69) | SMN1; SMN2NPC1TP53POLBRAB9A | |
| SCHEMBL5538061 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2MLYCDRORCRORA | |
| SCHEMBL13060491 | 0.77 | RAB9A (0.62) | SMN1; SMN2NPC1TP53POLBRAB9A | |
| SCHEMBL2081375 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2MLYCDRORCRORA | |
| SCHEMBL12994648 | 0.75 | POLB (0.66) | SMN1; SMN2NPC1TP53POLBRAB9A | |
| SCHEMBL3434346 | 0.75 | SMN1; SMN2 (0.71) | SMN1; SMN2MLYCDRORCNPC1POLB | |
| SCHEMBL11463482 | 0.75 | SMN1; SMN2 (0.71) | SMN1; SMN2MLYCDRORCPOLBRORA | |
| SCHEMBL12334561 | 0.74 | SMN1; SMN2 (0.65) | SMN1; SMN2MLYCDRORCRORA | |
| SCHEMBL13666660 | 0.74 | RAB9A (0.59) | SMN1; SMN2NPC1TP53POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | SMN1; SMN2 2021/4885MLYCD 6/4885RORC 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.